Shirazi Maryam Taghavi, Goodarzi Azadeh, Ghobadi Ali, Eghbalian Fatemeh
Department of Traditional Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical, Tehran, Iran.
Adv Biomed Res. 2024 Sep 23;13:91. doi: 10.4103/abr.abr_426_23. eCollection 2024.
Chronic spontaneous urticaria (CSU) is a challenging disorder that severely impacts the quality of life. The current study objective was to evaluate the efficacy and safety of jujube oxymel (JO) for treating CSU.
In this randomized double-blind controlled trial, 92 patients (aged 12-65) with CSU were randomly allocated to JO or placebo groups. They received 30cc of each syrup three times daily with 10 mg cetirizine for 28 days, subsequently taking 10 mg cetirizine alone for the next 4 weeks. Outcomes were evaluated using the weekly urticaria activity score (UAS-7) and Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
After four weeks, the UAS-7 score mean and standard deviation in the JO group significantly decreased to 10.89 ± 4.87 compared to the placebo group at 15.06 ± 7.55 (: 0.002). In the follow-up period, JO group participants achieved a score of 10.28 (4.67), while a significant increase occurred in the control group (18.33 ± 6.29) ( = 0.001). On day 28, there was a notable improvement in the quality of life within the JO group ( < 0.05). By the eighth week, both groups experienced an increase in CU-Q2oL score, but the changes in the control group were statistically significant (18.09 (5.96) vs 41.31 (10.34) (: 0.001).
JO, as part of integrated therapy, exhibited potentially longer-lasting efficacy than cetirizine alone, contributing to enhanced quality of life and increased patient satisfaction due to minimal side effects.
慢性自发性荨麻疹（CSU）是一种具有挑战性的疾病，严重影响生活质量。本研究的目的是评估枣子醋蜜（JO）治疗CSU的疗效和安全性。
在这项随机双盲对照试验中，92例12至65岁的CSU患者被随机分配到JO组或安慰剂组。他们每天三次服用30cc每种糖浆，并服用10mg西替利嗪，持续28天，随后在接下来的4周单独服用10mg西替利嗪。使用每周荨麻疹活动评分（UAS-7）和慢性荨麻疹生活质量问卷（CU-Q2oL）评估结果。
四周后，JO组的UAS-7评分平均值和标准差显著降至10.89±4.87，而安慰剂组为15.06±7.55（P = 0.002）。在随访期内，JO组参与者的评分为10.28（4.67），而对照组显著增加（18.33±6.29）（P = 0.001）。在第28天，JO组的生活质量有显著改善（P<0.05）。到第八周，两组的CU-Q2oL评分均有所增加，但对照组的变化具有统计学意义（18.09（5.96）对41.31（10.34）（P = 0.001）。
JO作为综合治疗的一部分，显示出比单独使用西替利嗪可能更持久的疗效，由于副作用最小，有助于提高生活质量和患者满意度。
